AGWCA
REGN icon

Annis Gardner Whiting Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53
Closed -$41K – 1039
2026
Q1 		$41K Buy
53
+8
+18% +$6.13K 0.01% 610
2025
Q4 		$34.7K Buy
45
+3
+7% +$2.04K 0.01% 582
2025
Q3 		$23.6K Sell
42
-5
-11% -$2.83K ﹤0.01% 588
2025
Q2 		$24.7K Buy
47
+36
+327% +$20.1K 0.01% 531
2025
Q1 		$6.98K Sell
11
-6
-35% -$4.13K ﹤0.01% 589
2024
Q4 		$12.1K Sell
17
-20
-54% -$16.8K ﹤0.01% 510
2024
Q3 		$38.9K Sell
37
-16
-30% -$17.8K 0.01% 393
2024
Q2 		$55.7K Buy
53
+10
+23% +$9.69K 0.02% 386
2024
Q1 		$41.4K Buy
43
+11
+34% +$10.5K 0.01% 412
2023
Q4 		$28.1K Buy
32
+1
+3% +$823 0.01% 363
2023
Q3 		$25.5K Buy
+31
New +$24.4K 0.01% 365

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's REGN Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 53 shares — an estimated $41K sold.

Annis Gardner Whiting Capital Advisors first reported a position in REGN in Q3 2023 and held it in 11 quarters. The position peaked at $55.7K in Q2 2024. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 53 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $41K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 11 quarters.
  • Annis Gardner Whiting Capital Advisors's Regeneron Pharmaceuticals position peaked at $55.7K in Q2 2024.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.